Table 3 Charateristics of Patients in the Korean Cohort (n = 61)
Parameter | N (%) |
|---|---|
Mean age (range), y | 48 (30.7–65.9) |
CDK4/6i course | |
Palbociclib | 61 (100%) |
Abemaciclib | 0 |
Ribociclib | 0 |
Endocrine therapy course | |
Aromatase inhibitor | 44 (72.1%) |
Fulvestrant | 6 (9.8%) |
Others | 11 (18.1%) |
Mean duration of CDK4/6i + ET treatment, month (range), m | 13.2 (0.7–39.8) |
Form of biopsy specimens | |
Fresh tissue | 25 (41.0%) |
FFPE | 36 (59.0%) |
Prior treatment | |
De novo | 22 (36.1%) |
Neo/Adjuvant chemotherapy | 39 (63.9%) |
Source of Biopsy | |
Breast | 38 (59.0%) |
Liver | 6 (9.8%) |
Bone | 4 (6.6%) |
Lung | 3 (4.9%) |
Others | 12 (19.7%) |